Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

s or likelihood of success of our product research and development programs; the status of our preclinical and clinical development of potential drugs; the likelihood of success of our drug products in clinical trials and the regulatory approval process; our drug products' efficacy, abuse and tamper resistance, onset and duration of drug action, ability to provide protection from overdose, ability to reduce the development of tolerance, ability to improve symptomatology or otherwise improve patients' symptoms; the incidence of adverse events; the ability to develop, manufacture, launch and market our drug products; our projections for future revenues, profitability and ability to achieve certain sales targets; our estimates regarding our capital requirements and our needs for additional financing; the likelihood of obtaining favorable scheduling and labeling of our drug products; the likelihood of regulatory approval under Section 505(b)(2) and other applicable Sections under the Federal Food, Drug, and Cosmetic Act; our ability to develop safer and improved versions of widely- prescribed drugs using our technology; and our ability to obtain favorable patent claims. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Cutanea Life Sciences does not undertake any obligation to republish revised forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com

Cutanea Life Sciences

Kimberley Forbes-McKean, Ph.D.

484-568-0106

KFMcKean@CutaneaLife.com


'/>"/>
SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... , Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... pharmacy, is proud to announce Jennifer Hagerman , ... Diplomat, will take office as the president of the ... induction ceremony will take place Feb. 28, 2015, at ... held at the Renaissance Center in Detroit, ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical ... company engaged primarily in the development of brachytherapy ... applications, today announced that it has filed a ... and Drug Administration ("FDA") for marketing clearance for ... 513(f)(2) of the U.S. Food, Drug and Cosmetic ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Sept. 28 Delcath Systems, Inc. (Nasdaq: DCTH ... Blair Emerging Growth Stock Conference on Tuesday, October 5, 2010 ... McDonald, Chief Financial Officer, will provide an overview of the ... at this conference is by invitation only. Delcath will offer ...
... be giving their children more medicine than they ... week at Research Forum during Scientific Assembly, the ... Physicians.  Two studies are raising concern about over-the-counter ... Inaccurate" and "Do Parents in the Emergency Department ...
Cached Medicine Technology:Delcath to Present at the William Blair Emerging Growth Stock Conference 2Warnings Re: Over-the-Counter Medication for Children: Less is More 2
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... over an existing treadmill and allows employees to walk and work simultaneously, ... ... 2008 -- Wouldn,t it be wonderful if there was a product that ... shed excess weight and make them more productive? , , , , ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
... Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading fully ... People,s Republic of China ("PRC"), announced today ... Co. Ltd.,("Harbin First Bio-Engineering"), received $800,000 in ...
... PLYMOUTH MEETING, Pa., Oct. 21 Genaera,Corporation (Nasdaq: ... NASDAQ that the bid price of the Company,s common ... under NASDAQ,Marketplace Rule 4310(c)(4) for the last 30 consecutive ... as of October 16, 2008 it has,suspended for a ...
... BASKING RIDGE, N.J., Oct. 21 Hooper ... Heritage Labs division was awarded a,contract to manufacture ... Westat, an employee-owned corporation providing research services,to agencies ... foundations, and,state and local governments. This component of ...
... are Effective in,Treating Triple-Negative Beast Cancer, According to ... Oct. 21 Decision Resources, one of the,world,s ... issues, finds that significant market penetration will drive,Genentech/Roche/Chugai,s ... total,sales in the breast cancer drug market in ...
Cached Medicine News:Health News:Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3Health News:China Sky One Medical, Inc. Receives Tax Refund 2Health News:China Sky One Medical, Inc. Receives Tax Refund 3Health News:Genaera Receives Non-Compliance Notice From NASDAQ 2Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 2Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 3Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 4Health News:Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017 2
For the quantitative in vitro determination of Carbamazepine in human serum...
For the quantitative in vitro determination of Phenobarbital in human serum....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with particulate (silica) activator....
Medicine Products: